Use of ATII antagonist for the treatment or prevention of metabolic syndrome

Details for Australian Patent Application No. 2004226517 (hide)

Owner AstraZeneca AB

Inventors Ljunggren, Anders; Svensson, Anders

Agent Davies Collison Cave

Pub. Number AU-B-2004226517

PCT Pub. Number WO2004/087136

Priority 0300988-3 03.04.03 SE

Filing date 31 March 2004

Wipo publication date 14 October 2004

Acceptance publication date 24 January 2008

International Classifications

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

Event Publications

29 September 2005 PCT application entered the National Phase

  PCT publication WO2004/087136 Priority application(s): WO2004/087136

24 January 2008 Application Accepted

  Published as AU-B-2004226517

22 May 2008 Standard Patent Sealed

25 October 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004226518-Chromatographic separation of substances contained in a liquid sample

2004226492-Method of inducing differentiation and proliferating regulatory T cell by antiCD52 antibody and medicinal composition therefor